FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to an imidazopyridine compound of formula I and pharmaceutically acceptable salts thereof, the structural formulas of which are given in the claim.
I
EFFECT: imidazopyridine compounds according to the invention are intended as Bruton's tyrosine kinase inhibitor (BTK).
3 cl, 5 tbl, 190 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY | 2015 |
|
RU2767460C2 |
| METHODS OF OBTAINING AND PURIFICATION OF HETEROARYL COMPOUNDS | 2010 |
|
RU2557242C2 |
| IMIDAZOTRIAZINONE COMPOUNDS | 2011 |
|
RU2603140C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| TRANSGLUTAMINASE 2 (TG2) INHIBITORS | 2019 |
|
RU2781370C2 |
| SELECTIVE KINASE JAK1 INHIBITOR | 2020 |
|
RU2818002C2 |
| MTOR KINASE INHIBITORS FOR ONCOLOGIC INDICATIONS AND DISEASES ASSOCIATED WITH MTOR/PI3K/AKT BY METABOLISM | 2009 |
|
RU2692796C2 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| INHIBITORS OF AKT ACTIVITY | 2010 |
|
RU2579513C2 |
| KINASE INHIBITORS APPLICABLE FOR TREATING MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | 2007 |
|
RU2482112C2 |
